Catalog No.: PC-38711Not For Human Use, Lab Use Only.
AMPC is a first-in-class small-molecule inhibitor of the oncogenic functions of trefoil factor 3 (TFF3) that specifically monomerizes dimeric TFF3 to inhibit dimeric TFF3 function, specifically binds to Cys57 of TFF3.
AMPC is a first-in-class small-molecule inhibitor of the oncogenic functions of trefoil factor 3 (TFF3) that specifically monomerizes dimeric TFF3 to inhibit dimeric TFF3 function, specifically binds to Cys57 of TFF3.
AMPC treatment decreased TFF3 protein levels in a dose-dependent manner in BT474 cells, with a significant reduction of TFF3 levels at 10 uM, decreased HER1-4 phosphorylation and phosphorylation of downstream AKT and p44/42 MAPK in a dose-dependent manner.
AMPC exhibited cell growth inhibition against BT474 and MDA-MB-361 cells with IC50 of 1.2 and 3.7 uM, respectively.
AMPC inhibition of TFF3 decreased monolayer cell viability, increased apoptosis and decreased 3D Matrigel growth of trastuzumab resistant BT474 cells, without re-sensitization to trastuzumab.
AMPC exhibited synergistic inhibitory effects on lung ADC cell growth when combined with various MEK1/2 inhibitors.
